Objective To investigate the therapeutic effects and mechanism of Qidan Granules(QDG)on glucose and lipid metabolism disorders in type 2 diabetes mellitus(T2DM).Methods Rats were randomly divided into normal group,model group,QDG low-dose group,QDG high-dose group,and QDG high-dose+PI3K inhibitor group.The normal group received standard chow,while other groups were fed a high-fat/high-sugar diet and injected with streptozotocin(STZ)to establish T2DM.After modeling,rats received corresponding treatments.General conditions were monitored,with body mass,fasting blood glucose(FBG),lipid profiles[total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],and fasting insulin levels recorded.Homeostatic model assessment of insulin resistance(HOMA-IR)was calculated.Hepatic mRNA expression of PI3K,AKT,and GSK3β was quantified via qRT-PCR,while protein levels of PI3K,AKT,GSK3β were measured by Western Blot.Results Compared with the model group,the QDG high-dose group showed reduced body mass(P＜0.05),reduced FBG(P＜0.05),decreased TC,TG,and LDL-C,elevated HDL-C,and lower HOMA-IR;mRNA levels of hepatic PI3K,AKT,and GSK3β and protein expression of p-PI3K,p-AKT,p-GSK3β were significantly upregulated,the differences being statistically significant(P＜0.05).The QDG low-dose and QDG high-dose+PI3K inhibitor groups exhibited attenuated improvements in these parameters versus the QDG high-dose group.Conclusion QDG ameliorates body mass loss,glucose/lipid metabolism,and insulin resistance in T2DM rats,likely by activating the PI3K/AKT/GSK3β pathway.